Intestinal permeation enhancers for oral peptide delivery

被引:288
作者
Maher, Sam [1 ]
Mrsny, Randall J. [2 ]
Brayden, David J. [3 ,4 ]
机构
[1] Royal Coll Surgeons Ireland, RCSI Sch Pharm, Dublin 2, Ireland
[2] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England
[3] Univ Coll Dublin, UCD Sch Vet Med, Dublin 4, Ireland
[4] Univ Coll Dublin, Conway Inst, Dublin 4, Ireland
基金
爱尔兰科学基金会;
关键词
Oral peptide delivery; Intestinal permeation enhancers; Paracellular transport; Transcellular; Solid dose formulation; Surfactants; Emulsions; TIGHT JUNCTION PERMEABILITY; TRIMETHYL CHITOSAN CHLORIDE; MOLECULAR-WEIGHT HEPARIN; BETA-LACTAM ANTIBIOTICS; CACO-2 CELL MONOLAYERS; MEDIUM-CHAIN GLYCERIDE; IN-VIVO EVALUATION; EPITHELIAL BARRIER FUNCTION; ZONULA-OCCLUDENS TOXIN; POORLY ABSORBABLE DRUG;
D O I
10.1016/j.addr.2016.06.005
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Intestinal permeation enhancers (PEs) are one of the most widely tested strategies to improve oral delivery of therapeutic peptides. This article assesses the intestinal permeation enhancement action of over 250 PEs that have been tested in intestinal delivery models. In depth analysis of pre-clinical data is presented for PEs as components of proprietary delivery systems that have progressed to clinical trials. Given the importance of co-presentation of sufficiently high concentrations of PE and peptide at the small intestinal epithelium, there is an emphasis on studies where PEs have been formulated with poorly permeable molecules in solid dosage forms and lipoidal dispersions. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:277 / 319
页数:43
相关论文
共 690 条
[1]
ADAMS RB, 1993, J IMMUNOL, V150, P2356
[2]
Aegis Therapeutics Llc, 2013, [No title captured], Patent No. [US20130034597, 20130034597]
[3]
Transport studies of insulin across rat jejunum in the presence of chicken and duck ovomucoids [J].
Agarwal, V ;
Nazzal, S ;
Reddy, IK ;
Khan, MA .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (08) :1131-1138
[4]
Agarwal Vikas, 2000, Pharmacy and Pharmacology Communications, V6, P223
[5]
Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials [J].
Aguirre, T. A. S. ;
Teijeiro-Osorio, D. ;
Rosa, M. ;
Coulter, I. S. ;
Alonso, M. J. ;
Brayden, D. J. .
ADVANCED DRUG DELIVERY REVIEWS, 2016, 106 :223-241
[6]
In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill®) of salmon calcitonin [J].
Aguirre, Tanira A. S. ;
Rosa, Monica ;
Coulter, Ivan S. ;
Brayden, David J. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 79 :102-111
[7]
Investigation of coco-glucoside as a novel intestinal permeation enhancer in rat models [J].
Aguirre, Tanira A. S. ;
Rosa, Monica ;
Guterres, Silvia S. ;
Pohlmann, Adriana R. ;
Coulter, Ivan ;
Brayden, David J. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2014, 88 (03) :856-865
[8]
Mechanism of IL-1β-induced increase in intestinal epithelial tight junction permeability [J].
Al-Sadi, Rana ;
Ye, Dongmei ;
Dokladny, Karol ;
Ma, Thomas Y. .
JOURNAL OF IMMUNOLOGY, 2008, 180 (08) :5653-5661
[9]
IL-1β causes an increase in intestinal epithelial tight junction permeability [J].
Al-Sadi, Rana M. ;
Ma, Thomas Y. .
JOURNAL OF IMMUNOLOGY, 2007, 178 (07) :4641-4649
[10]
Mechanistic understanding of oral drug absorption enhancement of cromolyn sodium by an amino acid derivative [J].
Alani, Adam W. G. ;
Robinson, Joseph R. .
PHARMACEUTICAL RESEARCH, 2008, 25 (01) :48-54